Evidence map›Paper›PMID 26130141›Full record

Trial reportScientific reports2015

Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial.

Chen-Hua Liu, Chung-Feng Huang, Chun-Jen Liu, Chia-Yen Dai, Jee-Fu Huang, Jou-Wei Lin, Cheng-Chao Liang, Sheng-Shun Yang, Chih-Lin Lin, Tung-Hung Su and 6 more

Abstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Scientific reports, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Chen-Hua Liu1] Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan [2] Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan [3] Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan [4] Department of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan.
Chung-Feng Huang1] Institute of Clinical Medicine and Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan [2] Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan [3] Department of Occupational Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung, Taiwan.
Chun-Jen Liu1] Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan [2] Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan [3] Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Chia-Yen Dai1] Institute of Clinical Medicine and Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan [2] Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Jee-Fu Huang1] Institute of Clinical Medicine and Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan [2] Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Jou-Wei LinDepartment of Internal Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou, Taiwan.
Cheng-Chao LiangDepartment of Internal Medicine, Far Eastern Memorial Hospital, Taipei, Taiwan.
Sheng-Shun YangDepartment of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan.
Chih-Lin LinDepartment of Gastroenterology, Taipei City Hospital, Ren-Ai Branch, Taipei, Taiwan.
Tung-Hung Su1] Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan [2] Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan [3] Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Hung-Chih Yang1] Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan [2] Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan [3] Department of Microbiology, National Taiwan University College of Medicine and National Taiwan University Hospital, Taipei.
Pei-Jer Chen1] Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan [2] Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan [3] Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Ding-Shinn Chen1] Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan [2] Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan [3] Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan [4] Genomics Research Center, Academia Sinica, Taiwan.
Wan-Long Chuang1] Institute of Clinical Medicine and Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan [2] Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
Jia-Horng Kao1] Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan [2] Hepatitis Research Center, National Taiwan University Hospital, Taipei, Taiwan [3] Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Ming-Lung Yu1] Institute of Clinical Medicine and Faculty of Internal Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan [2] Hepatobiliary Division, Department of Internal Medicine and Hepatitis Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan [3] Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung, Taiwan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatitis C virus genotype 2 (HCV-2) slow responders poorly respond to 24 weeks of peginterferon (Peg-IFN) plus ribavirin (RBV). We evaluated the efficacy of extended 48-week regimen and the role of interleukin-28B (IL-28B) genotype in this clinical setting. Treatment-naïve HCV-2 patients not achieving rapid virologic response (RVR) by Peg-IFN alfa-2a 180 μg/week plus weight-based RBV (1,000-1,200 mg/day, cutoff body weight of 75 kg) were randomly assigned to receive a total duration of 48 (n = 94) or 24 (n = 93) weeks of therapy. The primary endpoint was sustained virologic response (SVR). Baseline patient characteristics to predict SVR were analyzed. Patients receiving 48 weeks of treatment had a greater SVR rate than those receiving 24 weeks of treatment (70.2% versus 46.2%, P = 0.001). Compared to patients treated for 24 weeks, the SVR rate in those treated for 48 weeks increased by 10.9% [95% CI: -5.9% to 27.7%] and 65.6% [95% CI: 44.5% to 86.7%] if they had IL-28B rs8099917 TT genotype, and GT/GG genotype, respectively (interaction P = 0.002). In conclusion, 48-week treatment with Peg-IFN plus weight-based RBV provides a greater SVR rate than 24-week treatment in treatment-naïve HCV-2 patients with unfavorable IL-28B genotypes who fail to achieve RVR.

Indexed as

AdultAgedAntiviral AgentsDrug Administration ScheduleFemaleGenotypeHepacivirusHepatitis C, ChronicHumansInterferon-alphaInterferon LambdaInterferonsInterleukinsMaleMiddle AgedPolyethylene GlycolsAntiviral AgentsInterferon-alphaInterferon Lambdainterferon-lambda, humanInterferonsInterleukinspeginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsRibavirinRNA, Viral

Identifiers

PMID26130141
PMCPMC4486927

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.